Palladia 15mg Tablets

Description

Palladia is indicated for the treatment of recurrent canine cutaneous mast cell tumors of grade II (intermediate grade) or III (high grade) of Patnaik, non-excised.

Active substance: toceranib phosphate equivalent to 15mg.

Toceranib is a small molecule, multiple inhibitor of tyrosine kinase receptors, with direct anti-tumor and anti-angiogenic activity. Toceranib selectively inhibits multiple tyrosine kinase receptors (RTK), some of which are implicated in tumor growth, pathological angiogenesis and metastatic tumor progression. In biochemical and cellular assays, toceranib inhibited the activity of the Flk-1 / KDR tyrosine kinase (vascular endothelial growth factor receptor, VEGFR2), the platelet-derived growth factor receptor (PDGFR) and the cell factor receptor stem cells (c-kit). In-vitro, toceranib exhibited an antiproliferative effect on endothelial cells. Toceranib induces the end of the cell cycle and subsequent apoptosis in tumor cell lines that express active mutations in the RTK kinase, c-kit. The growth of canine mastocytoma frequently occurs with the activation of the mutation in the c-kit.

Posology and route of administration:

Oral use.

The tablets can be administered with or without food. The recommended starting dose is 3.25 mg toceranib / kg body weight, administered every other day.

The dose to be administered should be determined weekly by the veterinarian, for the first six weeks, and after every six weeks. The duration of treatment depends on the response to that treatment. Therapy with stable disease should be continued or if there is a partial or complete response to treatment, provided that the veterinary medicinal product is sufficiently well tolerated. In the event of tumor progression, treatment success is unlikely and therapy should be reassessed.

Because it is a veterinary medicinal product subject to medical prescription